• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Alpha Cognition gets $750,000 grant from US military for development of ALPHA-1062 intranasal galantamine for the treatment of brain injury

Alpha Cognition announced that the Army Medical Research and Material Command has awarded the company a $750,000 grant to support a pre-clinical study of the possible use of ALPHA-1062 Intranasal galantamine for the treatment of blast-induced mild traumatic brain injury (mTBI). According to Alpha Cognition, the study will be conducted in partnership with the Seattle Institute for Biomedical and Clinical Research. ALPHA-1062 is currently in development for the treatment of Alzheimer’s disease.

According to Alpha Cognition, the pre-clinical study is expected to start later this year and will take place over 16 months. The company said that a different pre-clinical study has already demonstrated that ALPHA-1062 can improve cognition and movement.

Alpha Cognition Chief Scientific Officer Denis Kay explained, “The body of evidence is growing to show that people who have suffered a TBI, even a mild TBI, are at greater risk of developing dementia in later life and are at risk for additional neurocognitive issues. An integral part of this research program will evaluate ALPHA-1062’ ability to reduce a toxic form of a brain protein, tau, known to be increased in this military relevant TBI model. Accumulation of toxic tau in the brain is linked to dementia progression, and was previously shown to be decreased by ALPHA-1062 in a separate pre-clinical model of moderate TBI. We are excited to embark upon a trial to provide additional evidence for reduction of one of the neuropathological drivers of increased dementia risk.”

Read the Alpha Cognition press release.

Share

published on June 8, 2023

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Catalent banner
    © 2025 OINDPnews